Macrophage Inflammatory Protein 1 Inhibits Postent
http://www.100md.com
病菌学杂志 2005年第9期
Institute for Medical Research at North Shore-LIJ, Center for Immunology and Inflammation, 350 Community Drive, Manhasset, New York 11030
North Shore University Hospital, Division of Infectious Disease, 300 Community Drive, Manhasset, New York 11030
ABSTRACT
Primary isolates of human immunodeficiency virus type 1 (HIV-1) predominantly use chemokine receptor CCR5 to enter target cells. The natural ligands of CCR5, the ?-chemokines macrophage inflammatory protein 1 (MIP-1), MIP-1?, and RANTES, interfere with HIV-1 binding to CCR5 receptors and decrease the amount of virions entering cells. Although the inhibition of HIV-1 entry by ?-chemokines is well documented, their effects on postentry steps of the viral life cycle and on host cell components that control the outcome of infection after viral entry are not well defined. Here, we show that all three ?-chemokines, and MIP-1 in particular, inhibit postentry steps of the HIV-1 life cycle in primary lymphocytes, presumably via suppression of intracellular levels of cyclic AMP (cAMP). Productive HIV-1 infection of primary lymphocytes requires cellular activation. Cell activation increases intracellular cAMP, which is required for efficient synthesis of proviral DNA during early steps of viral infection. Binding of MIP-1 to cognate receptors decreases activation-induced intracellular cAMP levels through the activation of inhibitory G proteins. Furthermore, inhibition of one of the downstream targets of cAMP, cAMP-dependent PKA, significantly inhibits synthesis of HIV-1-specific DNA without affecting virus entry. These data reveal that ?-chemokine-mediated inhibition of virus replication in primary lymphocytes combines inhibitory effects at the entry and postentry levels and imply the involvement of ?-chemokine-induced signaling in postentry inhibition of HIV-1 infection.
INTRODUCTION
The major cellular targets of human immunodeficiency virus type 1 (HIV-1) are CD4+ T lymphocytes and macrophages. Infection of these cells is initiated by interactions between viral envelope proteins and specific cellular receptors. In addition to CD4 glycoprotein, which is a major HIV-1 receptor, several members of the chemokine receptor family have been identified as coreceptors for HIV-1 (6, 11-13). Most primary strains of HIV-1 have an R5 phenotype and use CCR5, a member of the ?-chemokine receptor family, to enter target cells. The natural ligands of CCR5, the ?-chemokines macrophage inflammatory protein 1 (MIP-1), MIP-1?, and RANTES, represent host factors with potential anti-HIV-1 activity (7). In vitro studies clearly demonstrate that these molecules suppress HIV-1 entry into target cells by interfering with interactions between the virus and CCR5 receptors (27, 38, 39). However, the consequences of downstream signaling events induced by ?-chemokine binding to their cognate receptors, CCR5 and/or CCR1, on the replication of HIV-1 R5 strains are not well defined, although several studies show an effect of ?-chemokine-induced signaling on the replication of CXCR4-using viruses (15, 24).
Chemokine receptors belong to the superfamily of seven transmembrane-domain, G protein-coupled receptors. Several major intracellular signaling pathways are triggered by G protein-coupled receptors upon ligand binding. These pathways include the cyclic AMP (cAMP)/protein kinase A (PKA) pathway, the phosphatidylinositol/calcium/protein kinase C pathway, and the mitogen-activated protein kinase pathway (3, 14, 33). In eukaryotic cells, the cAMP/PKA pathway is one of the most common and versatile signaling pathways regulated by G protein-coupled receptors. Two G proteins, Gs and Gi, regulate intracellular levels of cAMP through the direct modulation of the activity of adenylyl cyclase, an enzyme that catalyzes the conversion of ATP to cAMP. Gs activates adenylyl cyclase, which results in increased cellular levels of cAMP, whereas Gi inhibits adenylyl cyclase.
Intracellular cAMP is a second messenger that influences metabolism, cell shape, chemokine receptor expression, and gene transcription via reversible protein phosphorylation (8, 34). Although cAMP has been shown to activate ion channels and Rap guanine exchange factors Epac 1 and 2 (reviewed in reference 26), the principal cAMP target is cAMP-dependent PKA. PKA is a serine/threonine kinase that regulates a number of cellular processes important for immune activation (37). Hyperactivation of the cAMP/PKA pathway has been implicated in the T-cell dysfunction associated with a common variable immunodeficiency (2) and HIV-1 infection (28). HIV-1 infection results in a functional impairment of CD4+ T cells before a quantitative decline becomes evident. The inability of T cells to generate a vigorous response to HIV-1 antigens continues to persist in patients on highly active antiretroviral therapy despite markedly reduced or undetectable levels of HIV-1 RNA. It has been shown that HIV-1 infection is associated with increased intracellular levels of cAMP and constitutive activation of PKA (19). Inhibition of the cAMP/PKA pathway, either by reducing intracellular cAMP levels with adenosine analogues (19) or PKA antagonists (1), can restore immune responses in T cells isolated from HIV-1-infected patients. Besides affecting T-cell responses, the cAMP/PKA pathway can accelerate HIV-1 replication directly (29, 31) as well as indirectly through modulation of cytokine production (9, 23). Furthermore, it has been shown recently that the active catalytic subunit of PKA (C-PKA) incorporates within highly purified HIV-1 particles and that impairment of host cell C-PKA activity by a synthetic inhibitor at the time of virus release results in the production of virions with reduced infectivity (5).
In this study, we demonstrate that MIP-1, in addition to inhibiting virus entry, inhibits postentry steps of the HIV-1 life cycle in primary lymphocytes via suppression of intracellular levels of cAMP. The magnitude of MIP-1-mediated postentry inhibition depends on activation-induced levels of intracellular cAMP, which are highly donor dependent. We further demonstrate that activation-induced levels of intracellular cAMP and active cAMP-dependent PKA contribute to the efficient synthesis of proviral DNA during early steps of the HIV-1 life cycle.
MATERIALS AND METHODS
Primary lymphocyte cultures. Peripheral blood mononuclear cells from healthy donors were obtained by Ficoll-Hypaque gradient centrifugation. To eliminate monocytes, cells were incubated for 2 h in PRIMARIA flasks (Falcon). Lymphocytes (nonadherent cells) were collected and subjected to the second round of purification by overnight adherence. Nonadherent cells recovered after the second round of adherence were greater than 80% CD3+, as determined by fluorescence-activated cell sorter analysis. Cells were then resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum and stimulated either with phytohemagglutinin (PHA) (5 μg/ml PHA) or with anti-CD3 antibody (1 μg/ml) coated onto plates. PHA was present in the culture medium for 3 days. Afterwards, cells were washed and resuspended in medium containing 20 U/ml of interleukin-2 (Roche). Cell proliferation was determined using an [3H]thymidine incorporation assay.
Viruses and infection. HIV-1 R5 strains HIV-1 ADA and HIV-1 92US660 were used in this study. Immediately before infection, an aliquot of the viral stock was treated with 200 U/ml of RNase-free DNase (Roche Molecular Biochemicals) to eliminate any viral DNA contamination. Cells were infected for 2 h at 37°C with an amount of virus corresponding to 5 x 104 cpm of reverse transcriptase activity per million cells. The amount of the virus was determined by a standard reverse transcriptase assay.
Cell assays. To analyze the effects of ?-chemokines on HIV infection, cells were treated with 200 ng/ml of MIP-1, MIP-1?, or RANTES, obtained from Serono Pharmaceuticals, at the times indicated. To determine the effects of MIP-1 on intracellular levels of cAMP in HIV-1-infected lymphocytes, PHA-stimulated cells were incubated with the virus for 1 h at 4°C to allow binding of the virus to cellular receptors. Following the addition of MIP-1, cells were incubated for two additional hours before preparing cell lysates for cAMP analysis. PKA inhibitors PKA 14-22 (a cell-permeable peptide inhibitor) and H89 (both from Calbiochem) were added to the cultures at the indicated concentrations 1 h before infection. Since H89 is solubilized in dimethyl sulfoxide (DMSO), parallel cultures were treated with DMSO alone to rule out the possibility that the observed effects on HIV-1 infection were due to solvent.
Analysis of intracellular cAMP. Cell lysates prepared from primary lymphocyte cultures were analyzed for levels of intracellular cAMP using a commercially available enzyme immunoassay system (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
Detection of HIV-1-specific DNA by PCR. Samples from infected cultures were prepared and subjected to PCR analysis using HIV-1-specific primers amplifying pol and long terminal repeat (LTR) RU5 transcripts as described previously (35). Amplified DNA was analyzed by Southern blot hybridization using 32P-labeled probes and quantified using an Instant Imager System (Packard). Results are expressed in counts per minute. Amplification of the -tubulin gene was used to control for the amount of DNA in each sample. Serial dilutions of 8E5/LAI cells, containing one HIV-1 genome per cell, were included in each amplification reaction to standardize the results.
Statistical analysis. Statistical and curve fit analysis of the correlation between cAMP levels and MIP-1-mediated postentry inhibition and the dependence of MIP-1-mediated decreases in intracellular cAMP on initial cAMP levels were performed using GraphPad Prism and Sigma Plot software packages, respectively. P values are considered significant when they are <0.05.
RESULTS
?-Chemokines inhibit postentry steps of HIV-1 infection in primary lymphocytes. Although in vitro studies clearly demonstrate that ?-chemokines inhibit HIV-1 entry into target cells, the consequences of chemokine-induced signaling events on viral replication are not well defined. In the current study, we examined whether ?-chemokine-induced signaling affects infection of primary cells with R5 strains of HIV-1 by focusing on the postentry steps of the viral life cycle. We treated primary lymphocytes with MIP-1, MIP-1?, or RANTES either before and after, before, or only after infection with HIV-1 ADA (R5 strain). In pretreated samples, ?-chemokines were also present during infection in order to prevent the reappearance of CCR5 receptors down-regulated during chemokine pretreatment and to further allow competition with the virus for receptor binding. Afterwards, we analyzed synthesis of HIV-1-specific DNA (pol transcripts) during one viral life cycle (24 h) by PCR. All three ?-chemokines inhibited HIV-1 DNA synthesis not only when they were present before and after or before infection but also when they were added only after infection with HIV-1 ADA (Fig. 1A). It has been shown previously that CCR5 receptors are resistant to trypsin treatment (41). Thus, in the next experiments we treated cells with trypsin immediately after incubation with the virus and prior to ?-chemokine treatment in order to verify that the inhibition is not due to the interference of ?-chemokines with the entry of residual noninternalized virus. The results obtained with trypsin-treated cells were similar to those presented in Fig. 1A (data not shown). These data indicate that ?-chemokines, in addition to inhibiting virus entry, inhibit postentry steps of the HIV-1 viral life cycle in primary lymphocytes. To further confirm this observation, we performed an additional set of experiments. It has been shown that HIV-1 can enter and initiate reverse transcription in quiescent lymphocytes; however, the reverse transcription process is not completed. The virus can be rescued from these cells by subsequent stimulation, which reinitiates DNA synthesis (40). Thus, we infected lymphocytes with the primary R5 isolate HIV-1 92US660 without prior activation. Cells were stimulated with anti-CD3 antibody and treated with ?-chemokines 72 h after infection as shown in the schematic (Fig. 1B, upper panel). All three ?-chemokines decreased synthesis of viral DNA under these experimental settings (Fig. 1B, bottom panel), thus confirming the inhibitory effect of ?-chemokines on postentry steps of the HIV-1 life cycle. Although we observed postentry inhibition in lymphocytes isolated from almost all blood donors, the magnitude of the inhibition varied among donors. Postentry inhibition ranged from 10 to 90%, independently of whether cells were activated with anti-CD3 or PHA. Furthermore, the relative efficacy of each chemokine varied from donor to donor. Since MIP-1 treatment gave the most consistent results (Fig. 2), with dose-dependent effects (Fig. 3), we decided to focus our study on MIP-1-mediated effects on HIV-1 infection.
MIP-1-mediated postentry inhibition is abolished by PTX and by exogenously supplied cAMP. MIP-1 can bind and signal through both CCR5 and CCR1. Previous studies demonstrated that chemokine binding induces coupling of both CCR5 and CCR1 to inhibitory G (Gi) proteins (25, 42). To determine whether MIP-1-mediated postentry inhibition of HIV-1 involves activation of Gi proteins, we incubated parallel cultures of lymphocytes in the presence or absence of 5 nM pertussis toxin (PTX) prior to HIV-1 infection and MIP-1 treatment. Pretreatment with PTX, a specific inhibitor of Gi protein signaling, abolished MIP-1-mediated inhibition without significantly affecting the levels of pol transcripts in infected cells that were not treated with MIP-1 (Fig. 4). Activated Gi proteins inhibit adenylyl cyclase, resulting in decreased intracellular levels of cAMP. Since the involvement of cAMP in the enhancement of HIV-1 replication has been demonstrated previously (29, 31), we reasoned that MIP-1 might inhibit synthesis of HIV-1-specific DNA via suppression of intracellular cAMP. We predicted that in such a case exogenously supplied cAMP would override the postentry inhibitory effect of MIP-1. As expected, treatment with a cell-permeable cAMP derivative, caged desyl cAMP, reversed the inhibitory effect of MIP-1 without significantly affecting virus infection in untreated cultures (Fig. 5). Similar results were obtained with forskolin, an activator of adenylyl cyclase (data not shown).
Activation-induced intracellular levels of cAMP are donor dependent and correlate with susceptibility of HIV-1 to MIP-1-mediated postentry inhibition. Thus far, our results indicate that cAMP is involved in synthesis of HIV-1-specific DNA during early steps of the viral life cycle and that MIP-1 inhibits postentry steps of the HIV-1 life cycle via modulation of intracellular cAMP levels. Next, we wished to determine mechanisms controlling donor-dependent variability in the magnitude of MIP-1-mediated postentry inhibition. Since lymphocyte activation (either through T-cell receptors or by PHA) is known to increase the amount and activity of Gs proteins, the activators of adenylyl cyclase (4, 20), we first examined whether the variability in MIP-1-mediated postentry inhibition could be linked to differences in activation-induced intracellular levels of cAMP. We analyzed intracellular cAMP levels in parallel cultures of lymphocytes (quiescent and PHA-stimulated) isolated from five blood donors. Our results (Fig. 6A) revealed a high degree of donor-dependent variability in activation-induced levels of cAMP. Next we examined whether high cAMP levels might restrain MIP-1-mediated postentry inhibition. We analyzed lymphocytes isolated from 10 blood donors for an association between activation-induced intracellular cAMP levels and magnitude of MIP-1-mediated inhibition of HIV-1-specific DNA synthesis. Regression analysis of the data yielded a significant inverse correlation between activation-induced cAMP levels and postentry inhibition (Fig. 6B). These results suggest that the efficacy of MIP-1-mediated suppression of intracellular cAMP might be limited in cells isolated from donors that respond to cell activation with large increases in intracellular cAMP. Indeed, analysis of intracellular cAMP in HIV-1-infected lymphocytes treated with MIP-1 and the comparison of detected levels to those in untreated cells revealed that MIP-1-mediated suppression of intracellular cAMP highly depends on activation-induced levels of cAMP (Fig. 6C).
Inhibition of cAMP-dependent PKA suppresses synthesis of HIV-1-specific DNA. One well-defined downstream target of cAMP is cAMP-dependent PKA, but other cAMP effectors have been identified as well (26). Therefore, we wanted to determine whether PKA is involved in the synthesis of HIV-1-specific DNA in primary lymphocytes. We treated cells with two different inhibitors of PKA, inhibitory peptide PKA 14-22 and chemical inhibitor H89, 1 h prior to infection with HIV-1 92US660 and analyzed HIV-1-specific pol transcripts 24 h later by PCR. Both inhibitors markedly suppressed synthesis of HIV-1-specific DNA in lymphocyte cultures (Fig. 7A). To verify that PKA regulates postentry steps of HIV-1 infection without affecting virus entry, we treated lymphocytes with PKA inhibitors as described above and infected them for 2 h. Afterwards, we analyzed the synthesis of HIV-1-specific strong-stop DNA (LTR RU5), the early product of reverse transcription synthesized shortly after viral entry. Cultures pretreated with MIP-1 served as a control. As can be seen in Fig. 7B, inhibition of PKA did not abolish HIV-1 entry into primary lymphocytes. Levels of strong-stop DNA were similar in treated and untreated samples, while pretreatment with MIP-1 markedly decreased these levels. These data suggest that PKA, a downstream target of cAMP, is involved in the regulation of HIV-1-specific DNA synthesis during early steps after virus entry.
DISCUSSION
In this study, we investigated the effects of ?-chemokines on postentry steps of HIV-1 infection in primary lymphocytes. The presented data indicate that ?-chemokine-induced signaling inhibits synthesis of HIV-1-specific DNA during early steps of the viral life cycle in this cellular target of the virus (Fig. 1). Focusing on the MIP-1-mediated inhibition, we show that MIP-1 suppresses activation-induced intracellular cAMP levels (Fig. 5 and 6C) through the activation of inhibitory G proteins (Fig. 4). The outcome of MIP-1-induced signaling depends on the state of activation of adenylyl cyclase, as reflected by intracellular levels of cAMP, and is highly donor dependent (Fig. 6A and B). Furthermore, our data demonstrate that inhibition of a downstream target of cAMP, cAMP-dependent PKA, results in the suppression of synthesis of HIV-1-specific DNA without affecting HIV-1 entry (Fig. 7). Altogether, our results support a model (Fig. 8) in which lymphocyte stimulation activates adenylyl cyclase, leading to increased cAMP levels and PKA activation. This cascade, most likely in combination with other cellular factors, contributes to the enhancement of synthesis of proviral DNA. Several studies have suggested that viral proteins might also increase intracellular cAMP (16, 28). The level of adenylyl cyclase activation might further affect the efficacy of chemokine-mediated postentry inhibition of HIV-1 infection. Our model proposes a dual activity for MIP-1. First, MIP-1 interferes with virus-CCR5 interactions, decreasing the number of virions entering the cells. Secondly, binding of MIP-1 to cognate receptors activates Gi proteins that inhibit adenylyl cyclase and decreases the intracellular levels of cAMP. Considering the complexity of the regulation of HIV-1 infection by a variety of viral and cellular factors, it is likely that other cellular factors are involved in the regulation of synthesis of proviral DNA during early steps of the HIV-1 life cycle and might be affected by chemokine-mediated signaling.
Several early studies have shown that increased intracellular levels of cAMP enhance HIV-1 replication, while inhibition of a downstream target of cAMP, cAMP-dependent PKA, has the opposite effect (18, 29-31). In their recent paper, Cartier et al. (5) demonstrate that active cAMP-dependent PKA is incorporated in HIV-1 particles where it interacts and possibly catalyzes phosphorylation of the viral CAp24gag protein, thus suggesting one mechanism by which cAMP/PKA modulates HIV-1 infection. Decreased amounts of virions with reduced infectivity are produced from cells transfected with pNL4-3 and cultivated in the presence of PKA inhibitors. Cartier et al. suggest that C-PKA plays a role in viral particle release as well as in either uncoating events or transcription or integration steps of the HIV-1 life cycle. Our results indicate that the cell-associated cAMP/PKA pathway might also modulate HIV-1 infection through the enhancement of synthesis of HIV-1-specific DNA during early postentry reverse transcription steps and is one of the targets of MIP-1-induced signaling. It is likely that the inhibition of HIV-1 replication during long-term cultivation in cells deprived of PKA activity might combine several mechanisms, since cAMP/PKA is a versatile pathway that can affect several cellular functions (reviewed in reference 36) required for efficient replication of the virus.
While several studies, including data presented here, show that the cAMP/PKA pathway enhances HIV-1 infection in lymphocytes, the studies in macrophages appear to yield quite different data. Hayes et al. (17) recently showed inhibition of HIV-1 replication in macrophages by prostaglandin E2 through the activation of PKA. Therefore, we analyzed the effects of ?-chemokines and PKA inhibitors on HIV-1 replication in primary macrophages. Interestingly, contrary to what we have shown for primary lymphocytes, in macrophages isolated from the same donors, neither ?-chemokines nor PKA inhibitors showed the inhibitory effects on postentry steps of the HIV-1 life cycle (data not shown). This might suggest that chemokines trigger signaling events in macrophages different from those induced in primary lymphocytes. However, considering the data published by Hayes et al. (17), a more likely explanation would be that cAMP/PKA might exert differential effects on HIV-1 replication in primary lymphocytes and macrophages.
The results presented in this report reveal that ?-chemokine-mediated inhibition of HIV-1 replication in primary lymphocyte cultures is complex and can be mediated through several mechanisms. Although it is difficult to extrapolate in vitro data to the in vivo setting, especially the relative importance of chemokine-mediated inhibition of entry versus postentry steps, it is plausible to envision a hypothetical implication of our data. It has been suggested that elevated ?-chemokine levels play an important role in preventing HIV-1 infection in uninfected individuals with multiple high-risk sexual exposures (21). However, different results have been reported when ?-chemokine levels were analyzed during established HIV-1 infection (22, 32) where other factors might counterbalance their inhibitory effects. Taking into consideration that increased intracellular cAMP levels and constitutively active PKA have been reported for HIV-1-infected patients (1, 10, 19), our studies raise the possibility that intracellular cAMP might be one of those host cellular factors counterbalancing the antiviral effects of ?-chemokines.
ACKNOWLEDGMENTS
This work was supported by NIH grants AI43743 (H.S.) and AI29110 (B.S.) and by the Picower Foundation.
We thank Amanda Proudfoot from Serono Pharmaceuticals for recombinant chemokines. HIV-1 ADA and HIV-1 92US660 were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.
REFERENCES
Aandahl, E. M., P. Aukrust, B. S. Skalhegg, F. Muller, S. S. Froland, V. Hansson, and K. Tasken. 1998. Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J. 12:855-862.
Aukrust, P., E. M. Aandahl, B. S. Skalhegg, I. Nordoy, V. Hansson, K. Tasken, S. S. Froland, and F. Muller. 1999. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J. Immunol. 162:1178-1185.
Blumer, K. J., and G. L. Johnson. 1994. Diversity in function and regulation of MAP kinase pathways. Trends Biochem. Sci. 19:236-240.
Buc, H. A., A. Moncion, M. Hamet, and J. L. Perignon. 1993. T-cell antigen receptor-mediated enhancement of the adenylate cyclase pathway depends on tyrosine protein kinases. Int. J. Immunopharmacol. 15:415-422.
Cartier, C., B. Hemonnot, B. Gay, M. Bardy, C. Sanchiz, C. Devaux, and L. Briant. 2003. Active cAMP-dependent protein kinase incorporated within highly purified HIV-1 particles is required for viral infectivity and interacts with viral capsid protein. J. Biol. Chem. 278:35211-35219.
Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. La Rosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
Cocchi, F., A. L. De Vico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
Cole, S. W., B. D. Jamieson, and J. A. Zack. 1999. cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. J. Immunol. 162:1392-1400.
Cole, S. W., Y. D. Korin, J. L. Fahey, and J. A. Zack. 1998. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J. Immunol. 161:610-616.
Cole, S. W., B. D. Naliboff, M. E. Kemeny, M. P. Griswold, J. L. Fahey, and J. A. Zack. 2001. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc. Natl. Acad. Sci. USA 98:12695-12700.
Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
Gilman, A. G. 1987. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56:615-649.
Gordon, C. J., M. A. Muesing, A. E. Proudfoot, C. A. Power, J. P. Moore, and A. Trkola. 1999. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine Rantes is independent of the mechanism of virus-cell fusion. J. Virol. 73:684-694.
Haraguchi, S., R. A. Good, M. James-Yarish, G. J. Cianciolo, and N. K. Day. 1995. Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections. Proc. Natl. Acad. Sci. USA 92:5568-5571.
Hayes, M. M., B. R. Lane, S. R. King, D. M. Markovitz, and M. J. Coffey. 2002. Prostaglandin E(2) inhibits replication of HIV-1 in macrophages through activation of protein kinase A. Cell. Immunol. 215:61-71.
Hofmann, B., P. Nishanian, T. Nguyen, P. Insixiengmay, and J. L. Fahey. 1993. Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes. Proc. Natl. Acad. Sci. USA 90:6676-6680.
Hofmann, B., P. Nishanian, T. Nguyen, M. Liu, and J. L. Fahey. 1993. Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues. AIDS 7:659-664.
Holter, W., A. M. Spiegel, B. H. Howard, S. Weber, and M. R. Brann. 1991. Expression of GTP-binding proteins and prostaglandin E2 receptors during human T cell activation. Cell. Immunol. 134:287-295.
Iversen, A. K., L. Fugger, J. Eugen-Olsen, U. Balslev, T. Jensen, S. Wahl, J. Gerstoft, J. I. Mullins, and P. Skinhoj. 1998. Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion. J. Infect. Dis. 178:1334-1342.
Jennes, W., S. Sawadogo, S. Koblavi-Deme, B. Vuylsteke, C. Maurice, T. H. Roels, T. Chorba, J. N. Nkengasong, and L. Kestens. 2002. Positive association between beta-chemokine-producing T cells and HIV type 1 viral load in HIV-infected subjects in Abidjan, Cote d'Ivoire. AIDS Res. Hum. Retrovir. 18:171-177.
Johansson, C. C., T. Bryn, A. Yndestad, H. G. Eiken, V. Bjerkeli, S. S. Froland, P. Aukrust, and K. Tasken. 2004. Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP. AIDS 18:171-179.
Kinter, A., A. Catanzaro, J. Monaco, M. Ruiz, J. Justement, S. Moir, J. Arthos, A. Oliva, L. Ehler, S. Mizell, R. Jackson, M. Ostrowski, J. Hoxie, R. Offord, and A. S. Fauci. 1998. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc. Natl. Acad. Sci. USA 95:11880-11885.
Ko, J., I. S. Kim, S. W. Jang, Y. H. Lee, S. Y. Shin, D. S. Min, and D. S. Na. 2002. Leukotactin-1/CCL15-induced chemotaxis signaling through CCR1 in HOS cells. FEBS Lett. 515:159-164.
Kopperud, R., C. Krakstad, F. Selheim, and S. O. Doskeland. 2003. cAMP effector mechanisms. Novel twists for an ‘old’ signaling system. FEBS Lett. 546:121-126.
Mack, M., B. Luckow, P. J. Nelson, J. Cihak, G. Simmons, P. R. Clapham, N. Signoret, M. Marsh, M. Stangassinger, F. Borlat, T. N. Wells, D. Schlondorff, and A. E. Proudfoot. 1998. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187:1215-1224.
Masci, A. M., M. Galgani, S. Cassano, S. De Simone, A. Gallo, V. De Rosa, S. Zappacosta, and L. Racioppi. 2003. HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. J. Leukoc. Biol. 74:1117-1124.
Nokta, M., J. Belli, and R. Pollard. 1992. X-irradiation enhances in vitro human immunodeficiency virus replication correlation with cellular levels of cAMP. Proc. Soc. Exp. Biol. Med. 200:402-408.
Nokta, M., and R. Pollard. 1991. Human immunodeficiency virus infection: association with altered intracellular levels of cAMP and cGMP in MT-4 cells. Virology 181:211-217.
Nokta, M. A., and R. B. Pollard. 1992. Human immunodeficiency virus replication: modulation by cellular levels of cAMP. AIDS Res. Hum. Retrovir. 8:1255-1261.
Paxton, W. A., T. Dragic, R. A. Koup, and J. P. Moore. 1996. The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. AIDS Res. Hum. Retrovir. 12:1203-1207.
Post, G. R., and J. H. Brown. 1996. G protein-coupled receptors and signaling pathways regulating growth responses. FASEB J. 10:741-749.
Rich, T. C., and J. W. Karpen. 2002. Cyclic AMP sensors in living cells: what signals can they actually measure? Ann. Biomed. Eng. 30:1088-1099.
Schmidtmayerova, H., M. Alfano, G. Nuovo, and M. Bukrinsky. 1998. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J. Virol. 72:4633-4642.
Shabb, J. B. 2001. Physiological substrates of cAMP-dependent protein kinase. Chem. Rev. 101:2381-2411.
Torgersen, K. M., T. Vang, H. Abrahamsen, S. Yaqub, and K. Tasken. 2002. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell. Signal. 14:1-9.
Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
Wu, L., N. P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A. A. Cardoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
Zack, J. A., A. M. Haislip, P. Krogstad, and I. S. Chen. 1992. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J. Virol. 66:1717-1725.
Zaitseva, M., A. Blauvelt, S. Lee, C. K. Lapham, V. Klaus-Kovtun, H. Mostowski, J. Manischewitz, and H. Golding. 1997. Expression and function of CCR5 and CXCR4 on human langerhans cells and macrophages: implications for HIV primary infection. Nat. Med. 3:1369-1375.
Zhao, J., L. Ma, Y. L. Wu, P. Wang, W. Hu, and G. Pei. 1998. Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization. J. Cell. Biochem. 71:36-45.(Carol-Ann Amella, Barbara)
North Shore University Hospital, Division of Infectious Disease, 300 Community Drive, Manhasset, New York 11030
ABSTRACT
Primary isolates of human immunodeficiency virus type 1 (HIV-1) predominantly use chemokine receptor CCR5 to enter target cells. The natural ligands of CCR5, the ?-chemokines macrophage inflammatory protein 1 (MIP-1), MIP-1?, and RANTES, interfere with HIV-1 binding to CCR5 receptors and decrease the amount of virions entering cells. Although the inhibition of HIV-1 entry by ?-chemokines is well documented, their effects on postentry steps of the viral life cycle and on host cell components that control the outcome of infection after viral entry are not well defined. Here, we show that all three ?-chemokines, and MIP-1 in particular, inhibit postentry steps of the HIV-1 life cycle in primary lymphocytes, presumably via suppression of intracellular levels of cyclic AMP (cAMP). Productive HIV-1 infection of primary lymphocytes requires cellular activation. Cell activation increases intracellular cAMP, which is required for efficient synthesis of proviral DNA during early steps of viral infection. Binding of MIP-1 to cognate receptors decreases activation-induced intracellular cAMP levels through the activation of inhibitory G proteins. Furthermore, inhibition of one of the downstream targets of cAMP, cAMP-dependent PKA, significantly inhibits synthesis of HIV-1-specific DNA without affecting virus entry. These data reveal that ?-chemokine-mediated inhibition of virus replication in primary lymphocytes combines inhibitory effects at the entry and postentry levels and imply the involvement of ?-chemokine-induced signaling in postentry inhibition of HIV-1 infection.
INTRODUCTION
The major cellular targets of human immunodeficiency virus type 1 (HIV-1) are CD4+ T lymphocytes and macrophages. Infection of these cells is initiated by interactions between viral envelope proteins and specific cellular receptors. In addition to CD4 glycoprotein, which is a major HIV-1 receptor, several members of the chemokine receptor family have been identified as coreceptors for HIV-1 (6, 11-13). Most primary strains of HIV-1 have an R5 phenotype and use CCR5, a member of the ?-chemokine receptor family, to enter target cells. The natural ligands of CCR5, the ?-chemokines macrophage inflammatory protein 1 (MIP-1), MIP-1?, and RANTES, represent host factors with potential anti-HIV-1 activity (7). In vitro studies clearly demonstrate that these molecules suppress HIV-1 entry into target cells by interfering with interactions between the virus and CCR5 receptors (27, 38, 39). However, the consequences of downstream signaling events induced by ?-chemokine binding to their cognate receptors, CCR5 and/or CCR1, on the replication of HIV-1 R5 strains are not well defined, although several studies show an effect of ?-chemokine-induced signaling on the replication of CXCR4-using viruses (15, 24).
Chemokine receptors belong to the superfamily of seven transmembrane-domain, G protein-coupled receptors. Several major intracellular signaling pathways are triggered by G protein-coupled receptors upon ligand binding. These pathways include the cyclic AMP (cAMP)/protein kinase A (PKA) pathway, the phosphatidylinositol/calcium/protein kinase C pathway, and the mitogen-activated protein kinase pathway (3, 14, 33). In eukaryotic cells, the cAMP/PKA pathway is one of the most common and versatile signaling pathways regulated by G protein-coupled receptors. Two G proteins, Gs and Gi, regulate intracellular levels of cAMP through the direct modulation of the activity of adenylyl cyclase, an enzyme that catalyzes the conversion of ATP to cAMP. Gs activates adenylyl cyclase, which results in increased cellular levels of cAMP, whereas Gi inhibits adenylyl cyclase.
Intracellular cAMP is a second messenger that influences metabolism, cell shape, chemokine receptor expression, and gene transcription via reversible protein phosphorylation (8, 34). Although cAMP has been shown to activate ion channels and Rap guanine exchange factors Epac 1 and 2 (reviewed in reference 26), the principal cAMP target is cAMP-dependent PKA. PKA is a serine/threonine kinase that regulates a number of cellular processes important for immune activation (37). Hyperactivation of the cAMP/PKA pathway has been implicated in the T-cell dysfunction associated with a common variable immunodeficiency (2) and HIV-1 infection (28). HIV-1 infection results in a functional impairment of CD4+ T cells before a quantitative decline becomes evident. The inability of T cells to generate a vigorous response to HIV-1 antigens continues to persist in patients on highly active antiretroviral therapy despite markedly reduced or undetectable levels of HIV-1 RNA. It has been shown that HIV-1 infection is associated with increased intracellular levels of cAMP and constitutive activation of PKA (19). Inhibition of the cAMP/PKA pathway, either by reducing intracellular cAMP levels with adenosine analogues (19) or PKA antagonists (1), can restore immune responses in T cells isolated from HIV-1-infected patients. Besides affecting T-cell responses, the cAMP/PKA pathway can accelerate HIV-1 replication directly (29, 31) as well as indirectly through modulation of cytokine production (9, 23). Furthermore, it has been shown recently that the active catalytic subunit of PKA (C-PKA) incorporates within highly purified HIV-1 particles and that impairment of host cell C-PKA activity by a synthetic inhibitor at the time of virus release results in the production of virions with reduced infectivity (5).
In this study, we demonstrate that MIP-1, in addition to inhibiting virus entry, inhibits postentry steps of the HIV-1 life cycle in primary lymphocytes via suppression of intracellular levels of cAMP. The magnitude of MIP-1-mediated postentry inhibition depends on activation-induced levels of intracellular cAMP, which are highly donor dependent. We further demonstrate that activation-induced levels of intracellular cAMP and active cAMP-dependent PKA contribute to the efficient synthesis of proviral DNA during early steps of the HIV-1 life cycle.
MATERIALS AND METHODS
Primary lymphocyte cultures. Peripheral blood mononuclear cells from healthy donors were obtained by Ficoll-Hypaque gradient centrifugation. To eliminate monocytes, cells were incubated for 2 h in PRIMARIA flasks (Falcon). Lymphocytes (nonadherent cells) were collected and subjected to the second round of purification by overnight adherence. Nonadherent cells recovered after the second round of adherence were greater than 80% CD3+, as determined by fluorescence-activated cell sorter analysis. Cells were then resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum and stimulated either with phytohemagglutinin (PHA) (5 μg/ml PHA) or with anti-CD3 antibody (1 μg/ml) coated onto plates. PHA was present in the culture medium for 3 days. Afterwards, cells were washed and resuspended in medium containing 20 U/ml of interleukin-2 (Roche). Cell proliferation was determined using an [3H]thymidine incorporation assay.
Viruses and infection. HIV-1 R5 strains HIV-1 ADA and HIV-1 92US660 were used in this study. Immediately before infection, an aliquot of the viral stock was treated with 200 U/ml of RNase-free DNase (Roche Molecular Biochemicals) to eliminate any viral DNA contamination. Cells were infected for 2 h at 37°C with an amount of virus corresponding to 5 x 104 cpm of reverse transcriptase activity per million cells. The amount of the virus was determined by a standard reverse transcriptase assay.
Cell assays. To analyze the effects of ?-chemokines on HIV infection, cells were treated with 200 ng/ml of MIP-1, MIP-1?, or RANTES, obtained from Serono Pharmaceuticals, at the times indicated. To determine the effects of MIP-1 on intracellular levels of cAMP in HIV-1-infected lymphocytes, PHA-stimulated cells were incubated with the virus for 1 h at 4°C to allow binding of the virus to cellular receptors. Following the addition of MIP-1, cells were incubated for two additional hours before preparing cell lysates for cAMP analysis. PKA inhibitors PKA 14-22 (a cell-permeable peptide inhibitor) and H89 (both from Calbiochem) were added to the cultures at the indicated concentrations 1 h before infection. Since H89 is solubilized in dimethyl sulfoxide (DMSO), parallel cultures were treated with DMSO alone to rule out the possibility that the observed effects on HIV-1 infection were due to solvent.
Analysis of intracellular cAMP. Cell lysates prepared from primary lymphocyte cultures were analyzed for levels of intracellular cAMP using a commercially available enzyme immunoassay system (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
Detection of HIV-1-specific DNA by PCR. Samples from infected cultures were prepared and subjected to PCR analysis using HIV-1-specific primers amplifying pol and long terminal repeat (LTR) RU5 transcripts as described previously (35). Amplified DNA was analyzed by Southern blot hybridization using 32P-labeled probes and quantified using an Instant Imager System (Packard). Results are expressed in counts per minute. Amplification of the -tubulin gene was used to control for the amount of DNA in each sample. Serial dilutions of 8E5/LAI cells, containing one HIV-1 genome per cell, were included in each amplification reaction to standardize the results.
Statistical analysis. Statistical and curve fit analysis of the correlation between cAMP levels and MIP-1-mediated postentry inhibition and the dependence of MIP-1-mediated decreases in intracellular cAMP on initial cAMP levels were performed using GraphPad Prism and Sigma Plot software packages, respectively. P values are considered significant when they are <0.05.
RESULTS
?-Chemokines inhibit postentry steps of HIV-1 infection in primary lymphocytes. Although in vitro studies clearly demonstrate that ?-chemokines inhibit HIV-1 entry into target cells, the consequences of chemokine-induced signaling events on viral replication are not well defined. In the current study, we examined whether ?-chemokine-induced signaling affects infection of primary cells with R5 strains of HIV-1 by focusing on the postentry steps of the viral life cycle. We treated primary lymphocytes with MIP-1, MIP-1?, or RANTES either before and after, before, or only after infection with HIV-1 ADA (R5 strain). In pretreated samples, ?-chemokines were also present during infection in order to prevent the reappearance of CCR5 receptors down-regulated during chemokine pretreatment and to further allow competition with the virus for receptor binding. Afterwards, we analyzed synthesis of HIV-1-specific DNA (pol transcripts) during one viral life cycle (24 h) by PCR. All three ?-chemokines inhibited HIV-1 DNA synthesis not only when they were present before and after or before infection but also when they were added only after infection with HIV-1 ADA (Fig. 1A). It has been shown previously that CCR5 receptors are resistant to trypsin treatment (41). Thus, in the next experiments we treated cells with trypsin immediately after incubation with the virus and prior to ?-chemokine treatment in order to verify that the inhibition is not due to the interference of ?-chemokines with the entry of residual noninternalized virus. The results obtained with trypsin-treated cells were similar to those presented in Fig. 1A (data not shown). These data indicate that ?-chemokines, in addition to inhibiting virus entry, inhibit postentry steps of the HIV-1 viral life cycle in primary lymphocytes. To further confirm this observation, we performed an additional set of experiments. It has been shown that HIV-1 can enter and initiate reverse transcription in quiescent lymphocytes; however, the reverse transcription process is not completed. The virus can be rescued from these cells by subsequent stimulation, which reinitiates DNA synthesis (40). Thus, we infected lymphocytes with the primary R5 isolate HIV-1 92US660 without prior activation. Cells were stimulated with anti-CD3 antibody and treated with ?-chemokines 72 h after infection as shown in the schematic (Fig. 1B, upper panel). All three ?-chemokines decreased synthesis of viral DNA under these experimental settings (Fig. 1B, bottom panel), thus confirming the inhibitory effect of ?-chemokines on postentry steps of the HIV-1 life cycle. Although we observed postentry inhibition in lymphocytes isolated from almost all blood donors, the magnitude of the inhibition varied among donors. Postentry inhibition ranged from 10 to 90%, independently of whether cells were activated with anti-CD3 or PHA. Furthermore, the relative efficacy of each chemokine varied from donor to donor. Since MIP-1 treatment gave the most consistent results (Fig. 2), with dose-dependent effects (Fig. 3), we decided to focus our study on MIP-1-mediated effects on HIV-1 infection.
MIP-1-mediated postentry inhibition is abolished by PTX and by exogenously supplied cAMP. MIP-1 can bind and signal through both CCR5 and CCR1. Previous studies demonstrated that chemokine binding induces coupling of both CCR5 and CCR1 to inhibitory G (Gi) proteins (25, 42). To determine whether MIP-1-mediated postentry inhibition of HIV-1 involves activation of Gi proteins, we incubated parallel cultures of lymphocytes in the presence or absence of 5 nM pertussis toxin (PTX) prior to HIV-1 infection and MIP-1 treatment. Pretreatment with PTX, a specific inhibitor of Gi protein signaling, abolished MIP-1-mediated inhibition without significantly affecting the levels of pol transcripts in infected cells that were not treated with MIP-1 (Fig. 4). Activated Gi proteins inhibit adenylyl cyclase, resulting in decreased intracellular levels of cAMP. Since the involvement of cAMP in the enhancement of HIV-1 replication has been demonstrated previously (29, 31), we reasoned that MIP-1 might inhibit synthesis of HIV-1-specific DNA via suppression of intracellular cAMP. We predicted that in such a case exogenously supplied cAMP would override the postentry inhibitory effect of MIP-1. As expected, treatment with a cell-permeable cAMP derivative, caged desyl cAMP, reversed the inhibitory effect of MIP-1 without significantly affecting virus infection in untreated cultures (Fig. 5). Similar results were obtained with forskolin, an activator of adenylyl cyclase (data not shown).
Activation-induced intracellular levels of cAMP are donor dependent and correlate with susceptibility of HIV-1 to MIP-1-mediated postentry inhibition. Thus far, our results indicate that cAMP is involved in synthesis of HIV-1-specific DNA during early steps of the viral life cycle and that MIP-1 inhibits postentry steps of the HIV-1 life cycle via modulation of intracellular cAMP levels. Next, we wished to determine mechanisms controlling donor-dependent variability in the magnitude of MIP-1-mediated postentry inhibition. Since lymphocyte activation (either through T-cell receptors or by PHA) is known to increase the amount and activity of Gs proteins, the activators of adenylyl cyclase (4, 20), we first examined whether the variability in MIP-1-mediated postentry inhibition could be linked to differences in activation-induced intracellular levels of cAMP. We analyzed intracellular cAMP levels in parallel cultures of lymphocytes (quiescent and PHA-stimulated) isolated from five blood donors. Our results (Fig. 6A) revealed a high degree of donor-dependent variability in activation-induced levels of cAMP. Next we examined whether high cAMP levels might restrain MIP-1-mediated postentry inhibition. We analyzed lymphocytes isolated from 10 blood donors for an association between activation-induced intracellular cAMP levels and magnitude of MIP-1-mediated inhibition of HIV-1-specific DNA synthesis. Regression analysis of the data yielded a significant inverse correlation between activation-induced cAMP levels and postentry inhibition (Fig. 6B). These results suggest that the efficacy of MIP-1-mediated suppression of intracellular cAMP might be limited in cells isolated from donors that respond to cell activation with large increases in intracellular cAMP. Indeed, analysis of intracellular cAMP in HIV-1-infected lymphocytes treated with MIP-1 and the comparison of detected levels to those in untreated cells revealed that MIP-1-mediated suppression of intracellular cAMP highly depends on activation-induced levels of cAMP (Fig. 6C).
Inhibition of cAMP-dependent PKA suppresses synthesis of HIV-1-specific DNA. One well-defined downstream target of cAMP is cAMP-dependent PKA, but other cAMP effectors have been identified as well (26). Therefore, we wanted to determine whether PKA is involved in the synthesis of HIV-1-specific DNA in primary lymphocytes. We treated cells with two different inhibitors of PKA, inhibitory peptide PKA 14-22 and chemical inhibitor H89, 1 h prior to infection with HIV-1 92US660 and analyzed HIV-1-specific pol transcripts 24 h later by PCR. Both inhibitors markedly suppressed synthesis of HIV-1-specific DNA in lymphocyte cultures (Fig. 7A). To verify that PKA regulates postentry steps of HIV-1 infection without affecting virus entry, we treated lymphocytes with PKA inhibitors as described above and infected them for 2 h. Afterwards, we analyzed the synthesis of HIV-1-specific strong-stop DNA (LTR RU5), the early product of reverse transcription synthesized shortly after viral entry. Cultures pretreated with MIP-1 served as a control. As can be seen in Fig. 7B, inhibition of PKA did not abolish HIV-1 entry into primary lymphocytes. Levels of strong-stop DNA were similar in treated and untreated samples, while pretreatment with MIP-1 markedly decreased these levels. These data suggest that PKA, a downstream target of cAMP, is involved in the regulation of HIV-1-specific DNA synthesis during early steps after virus entry.
DISCUSSION
In this study, we investigated the effects of ?-chemokines on postentry steps of HIV-1 infection in primary lymphocytes. The presented data indicate that ?-chemokine-induced signaling inhibits synthesis of HIV-1-specific DNA during early steps of the viral life cycle in this cellular target of the virus (Fig. 1). Focusing on the MIP-1-mediated inhibition, we show that MIP-1 suppresses activation-induced intracellular cAMP levels (Fig. 5 and 6C) through the activation of inhibitory G proteins (Fig. 4). The outcome of MIP-1-induced signaling depends on the state of activation of adenylyl cyclase, as reflected by intracellular levels of cAMP, and is highly donor dependent (Fig. 6A and B). Furthermore, our data demonstrate that inhibition of a downstream target of cAMP, cAMP-dependent PKA, results in the suppression of synthesis of HIV-1-specific DNA without affecting HIV-1 entry (Fig. 7). Altogether, our results support a model (Fig. 8) in which lymphocyte stimulation activates adenylyl cyclase, leading to increased cAMP levels and PKA activation. This cascade, most likely in combination with other cellular factors, contributes to the enhancement of synthesis of proviral DNA. Several studies have suggested that viral proteins might also increase intracellular cAMP (16, 28). The level of adenylyl cyclase activation might further affect the efficacy of chemokine-mediated postentry inhibition of HIV-1 infection. Our model proposes a dual activity for MIP-1. First, MIP-1 interferes with virus-CCR5 interactions, decreasing the number of virions entering the cells. Secondly, binding of MIP-1 to cognate receptors activates Gi proteins that inhibit adenylyl cyclase and decreases the intracellular levels of cAMP. Considering the complexity of the regulation of HIV-1 infection by a variety of viral and cellular factors, it is likely that other cellular factors are involved in the regulation of synthesis of proviral DNA during early steps of the HIV-1 life cycle and might be affected by chemokine-mediated signaling.
Several early studies have shown that increased intracellular levels of cAMP enhance HIV-1 replication, while inhibition of a downstream target of cAMP, cAMP-dependent PKA, has the opposite effect (18, 29-31). In their recent paper, Cartier et al. (5) demonstrate that active cAMP-dependent PKA is incorporated in HIV-1 particles where it interacts and possibly catalyzes phosphorylation of the viral CAp24gag protein, thus suggesting one mechanism by which cAMP/PKA modulates HIV-1 infection. Decreased amounts of virions with reduced infectivity are produced from cells transfected with pNL4-3 and cultivated in the presence of PKA inhibitors. Cartier et al. suggest that C-PKA plays a role in viral particle release as well as in either uncoating events or transcription or integration steps of the HIV-1 life cycle. Our results indicate that the cell-associated cAMP/PKA pathway might also modulate HIV-1 infection through the enhancement of synthesis of HIV-1-specific DNA during early postentry reverse transcription steps and is one of the targets of MIP-1-induced signaling. It is likely that the inhibition of HIV-1 replication during long-term cultivation in cells deprived of PKA activity might combine several mechanisms, since cAMP/PKA is a versatile pathway that can affect several cellular functions (reviewed in reference 36) required for efficient replication of the virus.
While several studies, including data presented here, show that the cAMP/PKA pathway enhances HIV-1 infection in lymphocytes, the studies in macrophages appear to yield quite different data. Hayes et al. (17) recently showed inhibition of HIV-1 replication in macrophages by prostaglandin E2 through the activation of PKA. Therefore, we analyzed the effects of ?-chemokines and PKA inhibitors on HIV-1 replication in primary macrophages. Interestingly, contrary to what we have shown for primary lymphocytes, in macrophages isolated from the same donors, neither ?-chemokines nor PKA inhibitors showed the inhibitory effects on postentry steps of the HIV-1 life cycle (data not shown). This might suggest that chemokines trigger signaling events in macrophages different from those induced in primary lymphocytes. However, considering the data published by Hayes et al. (17), a more likely explanation would be that cAMP/PKA might exert differential effects on HIV-1 replication in primary lymphocytes and macrophages.
The results presented in this report reveal that ?-chemokine-mediated inhibition of HIV-1 replication in primary lymphocyte cultures is complex and can be mediated through several mechanisms. Although it is difficult to extrapolate in vitro data to the in vivo setting, especially the relative importance of chemokine-mediated inhibition of entry versus postentry steps, it is plausible to envision a hypothetical implication of our data. It has been suggested that elevated ?-chemokine levels play an important role in preventing HIV-1 infection in uninfected individuals with multiple high-risk sexual exposures (21). However, different results have been reported when ?-chemokine levels were analyzed during established HIV-1 infection (22, 32) where other factors might counterbalance their inhibitory effects. Taking into consideration that increased intracellular cAMP levels and constitutively active PKA have been reported for HIV-1-infected patients (1, 10, 19), our studies raise the possibility that intracellular cAMP might be one of those host cellular factors counterbalancing the antiviral effects of ?-chemokines.
ACKNOWLEDGMENTS
This work was supported by NIH grants AI43743 (H.S.) and AI29110 (B.S.) and by the Picower Foundation.
We thank Amanda Proudfoot from Serono Pharmaceuticals for recombinant chemokines. HIV-1 ADA and HIV-1 92US660 were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.
REFERENCES
Aandahl, E. M., P. Aukrust, B. S. Skalhegg, F. Muller, S. S. Froland, V. Hansson, and K. Tasken. 1998. Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J. 12:855-862.
Aukrust, P., E. M. Aandahl, B. S. Skalhegg, I. Nordoy, V. Hansson, K. Tasken, S. S. Froland, and F. Muller. 1999. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J. Immunol. 162:1178-1185.
Blumer, K. J., and G. L. Johnson. 1994. Diversity in function and regulation of MAP kinase pathways. Trends Biochem. Sci. 19:236-240.
Buc, H. A., A. Moncion, M. Hamet, and J. L. Perignon. 1993. T-cell antigen receptor-mediated enhancement of the adenylate cyclase pathway depends on tyrosine protein kinases. Int. J. Immunopharmacol. 15:415-422.
Cartier, C., B. Hemonnot, B. Gay, M. Bardy, C. Sanchiz, C. Devaux, and L. Briant. 2003. Active cAMP-dependent protein kinase incorporated within highly purified HIV-1 particles is required for viral infectivity and interacts with viral capsid protein. J. Biol. Chem. 278:35211-35219.
Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. La Rosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
Cocchi, F., A. L. De Vico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
Cole, S. W., B. D. Jamieson, and J. A. Zack. 1999. cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. J. Immunol. 162:1392-1400.
Cole, S. W., Y. D. Korin, J. L. Fahey, and J. A. Zack. 1998. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J. Immunol. 161:610-616.
Cole, S. W., B. D. Naliboff, M. E. Kemeny, M. P. Griswold, J. L. Fahey, and J. A. Zack. 2001. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc. Natl. Acad. Sci. USA 98:12695-12700.
Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
Gilman, A. G. 1987. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56:615-649.
Gordon, C. J., M. A. Muesing, A. E. Proudfoot, C. A. Power, J. P. Moore, and A. Trkola. 1999. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine Rantes is independent of the mechanism of virus-cell fusion. J. Virol. 73:684-694.
Haraguchi, S., R. A. Good, M. James-Yarish, G. J. Cianciolo, and N. K. Day. 1995. Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections. Proc. Natl. Acad. Sci. USA 92:5568-5571.
Hayes, M. M., B. R. Lane, S. R. King, D. M. Markovitz, and M. J. Coffey. 2002. Prostaglandin E(2) inhibits replication of HIV-1 in macrophages through activation of protein kinase A. Cell. Immunol. 215:61-71.
Hofmann, B., P. Nishanian, T. Nguyen, P. Insixiengmay, and J. L. Fahey. 1993. Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes. Proc. Natl. Acad. Sci. USA 90:6676-6680.
Hofmann, B., P. Nishanian, T. Nguyen, M. Liu, and J. L. Fahey. 1993. Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues. AIDS 7:659-664.
Holter, W., A. M. Spiegel, B. H. Howard, S. Weber, and M. R. Brann. 1991. Expression of GTP-binding proteins and prostaglandin E2 receptors during human T cell activation. Cell. Immunol. 134:287-295.
Iversen, A. K., L. Fugger, J. Eugen-Olsen, U. Balslev, T. Jensen, S. Wahl, J. Gerstoft, J. I. Mullins, and P. Skinhoj. 1998. Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion. J. Infect. Dis. 178:1334-1342.
Jennes, W., S. Sawadogo, S. Koblavi-Deme, B. Vuylsteke, C. Maurice, T. H. Roels, T. Chorba, J. N. Nkengasong, and L. Kestens. 2002. Positive association between beta-chemokine-producing T cells and HIV type 1 viral load in HIV-infected subjects in Abidjan, Cote d'Ivoire. AIDS Res. Hum. Retrovir. 18:171-177.
Johansson, C. C., T. Bryn, A. Yndestad, H. G. Eiken, V. Bjerkeli, S. S. Froland, P. Aukrust, and K. Tasken. 2004. Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP. AIDS 18:171-179.
Kinter, A., A. Catanzaro, J. Monaco, M. Ruiz, J. Justement, S. Moir, J. Arthos, A. Oliva, L. Ehler, S. Mizell, R. Jackson, M. Ostrowski, J. Hoxie, R. Offord, and A. S. Fauci. 1998. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc. Natl. Acad. Sci. USA 95:11880-11885.
Ko, J., I. S. Kim, S. W. Jang, Y. H. Lee, S. Y. Shin, D. S. Min, and D. S. Na. 2002. Leukotactin-1/CCL15-induced chemotaxis signaling through CCR1 in HOS cells. FEBS Lett. 515:159-164.
Kopperud, R., C. Krakstad, F. Selheim, and S. O. Doskeland. 2003. cAMP effector mechanisms. Novel twists for an ‘old’ signaling system. FEBS Lett. 546:121-126.
Mack, M., B. Luckow, P. J. Nelson, J. Cihak, G. Simmons, P. R. Clapham, N. Signoret, M. Marsh, M. Stangassinger, F. Borlat, T. N. Wells, D. Schlondorff, and A. E. Proudfoot. 1998. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187:1215-1224.
Masci, A. M., M. Galgani, S. Cassano, S. De Simone, A. Gallo, V. De Rosa, S. Zappacosta, and L. Racioppi. 2003. HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. J. Leukoc. Biol. 74:1117-1124.
Nokta, M., J. Belli, and R. Pollard. 1992. X-irradiation enhances in vitro human immunodeficiency virus replication correlation with cellular levels of cAMP. Proc. Soc. Exp. Biol. Med. 200:402-408.
Nokta, M., and R. Pollard. 1991. Human immunodeficiency virus infection: association with altered intracellular levels of cAMP and cGMP in MT-4 cells. Virology 181:211-217.
Nokta, M. A., and R. B. Pollard. 1992. Human immunodeficiency virus replication: modulation by cellular levels of cAMP. AIDS Res. Hum. Retrovir. 8:1255-1261.
Paxton, W. A., T. Dragic, R. A. Koup, and J. P. Moore. 1996. The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons. AIDS Res. Hum. Retrovir. 12:1203-1207.
Post, G. R., and J. H. Brown. 1996. G protein-coupled receptors and signaling pathways regulating growth responses. FASEB J. 10:741-749.
Rich, T. C., and J. W. Karpen. 2002. Cyclic AMP sensors in living cells: what signals can they actually measure? Ann. Biomed. Eng. 30:1088-1099.
Schmidtmayerova, H., M. Alfano, G. Nuovo, and M. Bukrinsky. 1998. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J. Virol. 72:4633-4642.
Shabb, J. B. 2001. Physiological substrates of cAMP-dependent protein kinase. Chem. Rev. 101:2381-2411.
Torgersen, K. M., T. Vang, H. Abrahamsen, S. Yaqub, and K. Tasken. 2002. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell. Signal. 14:1-9.
Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187.
Wu, L., N. P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A. A. Cardoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
Zack, J. A., A. M. Haislip, P. Krogstad, and I. S. Chen. 1992. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J. Virol. 66:1717-1725.
Zaitseva, M., A. Blauvelt, S. Lee, C. K. Lapham, V. Klaus-Kovtun, H. Mostowski, J. Manischewitz, and H. Golding. 1997. Expression and function of CCR5 and CXCR4 on human langerhans cells and macrophages: implications for HIV primary infection. Nat. Med. 3:1369-1375.
Zhao, J., L. Ma, Y. L. Wu, P. Wang, W. Hu, and G. Pei. 1998. Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization. J. Cell. Biochem. 71:36-45.(Carol-Ann Amella, Barbara)